Top 5 Moves
- David Sveen added to Heska's board of directors
- Maritime Bank CEO James Maas to retire
- Akamai elects Bernardus Verwaayen to board
- China Ceramics announces resignations of two board members
- Raymond Jones takes new post at Bombardier Aerospace
Don't Miss Most Read
- Time to visit Lucerne
- For a polio-free world
- You can't beat the numbers: Windows 7 retail ends
- Women in Europe still work 59 days 'for free'
- Akamai to buy Prolexic for $370 million
- At the doorstep of the Great Barrier Reef
- Aruba - One Happy Island
- Custom-built Sunreef for blue waters
- Red flowing passion
- Sleeping with Signoria Di Firenze in old Hollywood style
- Connect with nature in eco swimming pool
- We don't need new BlackBerry
- Love me and I will love you
- Exercising with professor Eisenstein
- God bless you!
- China's trade surplus hit record high
- German biodiesel exports jumps this year
- Blind man sees with help from tooth
- Placebo improves both pleasure and pain
Download Windows Gadget
Afraxis appoints president and CEOApril 30, 2013, San Diego, Ca., USA- Afraxis, Inc., a biotechnology company, announced that it has appointed Carmine Stengone as the company's president and chief executive officer.
Mr. Stengone has more than 14 years of experience in the pharmaceutical and biotechnology industries, including positions in finance, strategic planning, corporate development, licensing, alliance management and venture funding.
In addition to his role as CEO of Afraxis, Inc., Mr. Stengone also serves as chief business officer for Avelas Biosciences, an Avalon Ventures Portfolio VIII company. Prior to joining Afraxis, he was with Phenomix Corporation from 2006 to 2010, where he was responsible for strategic collaborations and licensing agreements.
He was also a member of the Phenomix executive management team as the senior director of business development. Mr. Stengone served as senior manager of business development and strategic marketing for Anadys Pharmaceuticals, Inc. from 2004 to 2006. Prior to that, Mr. Stengone held a variety of positions at Johnson & Johnson Pharmaceutical Research and Development.
Mr. Stengone received his MBA from Johnson Graduate School of Management at Cornell University. He also holds a M.S. degree in organic chemistry from Duke University and a B.S. in chemistry from Wake Forest University.
The company has also appointed Christopher Rex as chief scientific officer.
Dr. Rex currently leads scientific operations at Afraxis Inc. and oversees the development of the ESP platform and other technologies.
Prior to his appointment as chief scientific officer, he was a principle investigator and director of R&D strategy for Afraxis Holdings from 2010-2013 during which time he developed the foundations of the ESP program to rapidly evaluate drug impact on the hallmark dendritic spine abnormalities in the Fmr1-knockout mouse model of Fragile-X Syndrome.
Dr. Rex trained in the neurobiology of learning and memory at University of California, Irvine, where he contributed over 20 scientific publications in top-tier neuroscience journals. Dr. Rex combines his diverse aptitudes ranging from biophotonics to cognitive enhancement to software design for virtual environments to inject innovations into CNS drug discovery and development.
Dr. Rex has received distinguished honors including selection as a NIH Earl Stadtman Investigator Finalist and a Kauffman Foundation Entrepreneurial Fellow.